Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FTC Clears Barr’s Acquisition Of Pliva Based On Divestiture Of Generic Drugs

This article was originally published in The Pink Sheet Daily

Executive Summary

Barr must divest three generic products – trazodone, triamterene/HCTZ and nimodipine – to Apotex and Banner.

You may also be interested in...



Watson/Actavis Merger Requires Near Record Divestiture; Sandoz, Par Pick Up 18 Products

The required divestitures are quite significant relative to the size of the transaction: this is the second-largest divesture, but only the fifth-largest merger of generic firms.

Barr Shifts Roles At The Top, Splits Up Senior Management Duties

Restructure frees CEO Downey of responsibilities he assumed when Bisaro jumped to Watson in August.

Barr Shifts Roles At The Top, Splits Up Senior Management Duties

Restructure frees CEO Downey of responsibilities he assumed when Bisaro jumped to Watson in August.

Related Content

Topics

UsernamePublicRestriction

Register

OM007016

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel